USOR 19062 - Ph 1b/3 Taze w/ R2 R/R Fol Lymph

A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma (EZH-302)

Disease Types: Lymphoma

Available at: Arlington Heights, Niles